FindTrial
Sign In

The pathophysiological role of autophagy and multivesicular bodies in patients with diabetic cardiomyopathy

The biogenesis and regulation of MVBs and autophagy in diabetic cardiomyopathy

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900021420
Enrollment
Unknown
Registered
2019-02-20
Start date
2019-02-21
Completion date
Unknown
Last updated
2019-02-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetic cardiomyopathy

Interventions

patients with diabetic cardiomyopathy:Nil
patients without diabetic cardiomyopathy:Nil

Sponsors

The Guoyao Dongfeng General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
21 Years to 88 Years

Inclusion criteria

Inclusion criteria: 1. HbA1c=6.5%; 2. FPG=7.0mmol/L (Without calore intake at least for 8 hours; 3. OGTT 2h=11.1mmol/L; 4. Patients with typical hyperglycemic or hyperglycemic symptoms, the random blood glucose=11.1mmol/L.

Exclusion criteria

Exclusion criteria: Stress hyperglycemia because of drug/pain etc, adverse effects on the target organs such as the heart, the brain, the kidney, heart failure,and so on, acute infection or by corresponding treatment, coronary heart disease, diabetes,adiposity, dyslipidemia, damaged liver or kidney functions,positive urinary protein, heart valve disease, stroke, TIA, thyroid disease, cancer, fever, gout, primary kidney disease.

Design outcomes

Primary

MeasureTime frame
autophagy and endosomes;—

Countries

China

Contacts

Public ContactZheng Cheng

Department of Cardiology, Tangdu Hospital, Fourth Military Medical University, Xi’an, China

13593737568@139.com+86 13593737568

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026